Clinical Trials Logo

APS-related Hyperprolactinaemia clinical trials

View clinical trials related to APS-related Hyperprolactinaemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00952757 Completed - Schizophrenia Clinical Trials

Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine

Start date: June 2007
Phase: N/A
Study type: Observational

Hyperprolactinaemia is a common side effect of some antipsychotics (APS), including some atypicals. Clinical consequences of hyperprolactinaemia are broad including amenorrhea, galactorrhea, tender breasts, gynecomastia and sexual dysfunction. Less known but also present is the increased cardiovascular risk, specially in women, disorders of osteoporotic type and a potential increased risk of breast and prostate cancer. Despite this growing evidence, there are no consistent published data in order to adopt evidence-based decisions that may be beneficial for the patient. This naturalistic observational 6 months follow-up study on patients with APS-induced hyperprolactinemia aims to obtain more information about the switching approach in cases of hyperprolactinemia secondary to APS and to better establish the role of switching to quetiapine (APS not related with the increase prolactin levels) in this problem.